About us
-
30K+ Orders fullfilled -
24/7 Support availability -
1000+ Project's completed -
25mio Business volume

Solovya – A new chapter in the hemp industry
To create World’s finest cannabinoid experiences.

Our Milestones
-
2021
Founding of Solovya & strategic brand positioning
Solovya is founded with a clear mission: to set a new standard in the hemp industry. From day one, our focus lies on quality, compliance, and long-term brand building across Europe. -
2022
Establishment of Czech production site & scaling operations
We open our first dedicated facility in the Czech Republic, expanding our production capacity and securing full control over manufacturing, sourcing, and quality assurance. -
2023
European product launch & market expansion
We successfully introduce our first line of premium hemp-based products across multiple EU markets. Solovya begins to establish itself as a trusted name in the cannabinoid industry. -
2024
Innovation of proprietary cannabinoid formulations
Solovya’s R&D team develops next-generation cannabinoid blends with enhanced bioavailability and stability. New product formats and applications are prepared for regulated markets. -
2025
GMP-certified production & medical cannabis launch
We establish a new GMP facility in Germany for pharmaceutical-grade raw materials. In Q4, Solovya obtains regulatory approval for medical cannabis in Germany and officially launches its first line of prescription-based products.
Our heads
-
Vincent Popp
Chief Executive Officer (CEO) -
Franziska Wunsch
Chief Financial Officer (CFO) -
Matthias Bednorz
Chief Technology Officer (CTO) -
Benjamin Popp
Chief Growth Officer (CGO) -
Ladislav Dudy-Koťo
Chief Operating Officer (COO)